celecoxib

health

Ultra-Low-Dose Immunotherapy Found to Extend Survival in Head and Neck Cancer

Phase III trial shows TMC-I regimen significantly improves survival over standard chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma.